Fina Biosolutions and PATH Contract for Manufacturing Development and Scale-up of EcoCRM

Fina Biosolutions and PATH Contract for Manufacturing Development and Scale-up of EcoCRM

Fina Biosolutions LLC announced today it has reached agreement with PATH, a global organization focused on solving some of the world’s most pressing health challenges, under which PATH will provide funding and technical support for the clinical manufacture of FinaBio’s CRM197, known commercially as EcoCRM®. As consideration for this support, FinaBio has licensed PATH its CRM197, a key component in conjugate vaccines. Under the license, PATH receives non-exclusive rights to EcoCRM® for infectious disease vaccines sold to, or for supply to, low-income countries.

Click here to read more.

URL link to full story
https://www.businesswire.com/news/home/20181115005121/en/Fina-Biosolutions-PATH-Contract-Manufacturing-Development-Scale-up
Media Contact
Dr. Andrew Lees
301-633-0464
Comments are closed.